Ebola virus disease: An update on current prevention and management strategies

M. A. Trad; W. Naughton; A. Yeung; L. Mazlin; N. M. Gilroy; D. A. Fisher; R. L. Stuart

doi:10.1016/j.jcv.2016.11.005

Ebola virus disease: An update on current prevention and management strategies

M. A. Trad, W. Naughton, A. Yeung, L. Mazlin, N. M. Gilroy, D. A. Fisher, R. L. Stuart

Research output: Contribution to journal › Review Article › Research › peer-review

19 Citations (Scopus)

Abstract

Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014–15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD.

Original language	English
Pages (from-to)	5-13
Number of pages	9
Journal	Journal of Clinical Virology
Volume	86
DOIs	https://doi.org/10.1016/j.jcv.2016.11.005
Publication status	Published - 1 Jan 2017

Keywords

Ebola
Ebolavirus
Management
Outbreak
Therapeutics
Vaccines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jcv.2016.11.005

Cite this

@article{25ec1891c3854a5c81483cd8ff6a6d5a,

title = "Ebola virus disease: An update on current prevention and management strategies",

abstract = "Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014–15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD.",

keywords = "Ebola, Ebolavirus, Management, Outbreak, Therapeutics, Vaccines",

author = "Trad, {M. A.} and W. Naughton and A. Yeung and L. Mazlin and Gilroy, {N. M.} and Fisher, {D. A.} and Stuart, {R. L.}",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/j.jcv.2016.11.005",

language = "English",

volume = "86",

pages = "5--13",

journal = "Journal of Clinical Virology",

issn = "1386-6532",

publisher = "Elsevier",

}

TY - JOUR

T1 - Ebola virus disease

T2 - An update on current prevention and management strategies

AU - Trad, M. A.

AU - Naughton, W.

AU - Yeung, A.

AU - Mazlin, L.

AU - Gilroy, N. M.

AU - Fisher, D. A.

AU - Stuart, R. L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014–15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD.

AB - Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014–15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD.

KW - Ebola

KW - Ebolavirus

KW - Management

KW - Outbreak

KW - Therapeutics

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84998992716&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2016.11.005

DO - 10.1016/j.jcv.2016.11.005

M3 - Review Article

AN - SCOPUS:84998992716

SN - 1386-6532

VL - 86

SP - 5

EP - 13

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

ER -

Ebola virus disease: An update on current prevention and management strategies

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this